Replies to post #581325 on NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

Agreed. I have been living and breathing this world in the neurology medical device space for 20 years. These reimbursement challenges and dynamics are fairly similar in medical device space. Although pharma is even worse!

Also, have couple of very close college friends at big pharmas like Roche & AstraZeneca in top management positions.

[hoffmann6383]

I find it super bullish that the disappointment narratives now include RA approvals as a foregone conclusion but are now trying to talk down the positive effect of said approvals.

Have a good one Sip!

[CrashOverride]

DCVax has a very high QLAY benefit for older patients especially considering the compassionate use data released by Bosch on 3/15/2023. Orphan and rare diseases have a threshold of 100K per QLAY but DCVax will be well under that limit. DCVax will be approved by MHRA and NICE this year.

All my opinion based upon published regulatory criteria.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169141878